AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04028856 — intervention group
Intervention type: DRUG
Intervention: interferon
Description: Chronic hepatitis B patients were treated with interferon for 48 weeks
Study NCT02827396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions.
Study NCT05568316 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative Immunonutrition
Description: Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period.
Study NCT05568316 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Perioperative Immunonutrition
Description: Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period.
Study NCT04429867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
Study NCT04429867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
Study NCT01418950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written information and verbal counseling
Description: control group will only receive verbal counseling. Study group will receive written information before verbal counseling
Study NCT01418950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written information and verbal counseling
Description: control group will only receive verbal counseling. Study group will receive written information before verbal counseling
Study NCT02871050 — intervention group
Intervention type: OTHER
Intervention: Sample Collection
Description: Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
Study NCT02951195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-152
Description: Tablet for oral administration.
Study NCT02951195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.
Study NCT02951195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.
Study NCT02951195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT02951195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Tablet for oral administration.
Study NCT02951195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-152.
Study NCT02951195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-152/TEZ/IVA triple combination (TC).
Study NCT05632796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjusting the Pfannenstiel skin incision according to the occipitofrontal diameter (OFD) of the fetal head.
Description: All women will be subjected to regional spinal anesthesia. Pfannenstiel incision will be made according to the fetal occiputofrontal diameter, marked on the skin (Pfannenstiel incison with Kaya modification) Following blunt entry to the abdominal cavity, the uterine lower segment Kerr incision will be performed. Folllowing delivery of the baby, umblical cord will be cut and an arterial umblical cord blood sample will be taken. Placenta will be removed. 1st and 5th min. Apgar scores will be noted. Uterine incison will be sutured double-layer with 1 polyglactin 910 suture . Peritoneum and fascia, will be closed with 2-0 and 1 polyglactin 910 suture respectively. Skin incision will be sutured with continuous 3-0 rapid polyglactin 910 suture and measured with flexible ruler in centimeters following completing the skin incision closure.
Study NCT03380130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: An anti-programmed death 1 monoclonal antibody
Study NCT03380130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres
Description: Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation
Study NCT03623893 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Contralateral exploration
Description: Surgery eventually performed when a patent processus vaginalis or hernia exists on the other side than the side on which the child has to be operated on, will be exactly the same as the inguinal hernia repair on the 'symptomatic' side. Exploration of the contralateral side will increase anaesthesia time by 10-15 minutes.
Study NCT00879541 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biostate® [SP]
Description: Single bolus intravenous dose of 50 IU/kg
Study NCT00879541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate® [SP]
Description: The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.
Study NCT00879541 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biostate® [RP]
Description: Single bolus intravenous dose of 50 IU/kg.
Study NCT02857387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample withdrawn
Study NCT00566280 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Molecular Breast Imaging
Description: A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
Study NCT03290313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: shu gan yi yang capsule
Description: Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
Study NCT03290313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: shu gan yi yang capsule simulation agent
Description: Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
Study NCT03290313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Description: Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
Study NCT03290313 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive psychotherapy
Description: Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
Study NCT03108274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Oral tablet.
Study NCT03108274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Oral tablet.
Study NCT03109730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
Study NCT03109730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731
Description: Sugar pill manufactured to mimic the ABI-H0731 tablet
Study NCT03109730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: An antiviral medication used in the treatment of hepatitis B virus infection
Study NCT03109730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: An antiviral medication used in the treatment of hepatitis B virus infection
Study NCT03109730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Used to treat adults with chronic hepatitis B virus who show signs of liver damage
Study NCT04915898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Hygiene - teeth brushing
Description: Oral hygiene using a special kit with recommended materials and instructions: Use of an ADA approved toothbrush, toothpaste with dentifrice, antiseptic mouthwash and non-drying lip moisturizer encouraged after meals and at bedtime
Study NCT02328183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B
Description: administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
Study NCT01512212 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: biopsy
Description: fnab
Study NCT00850070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin
Description: Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
Study NCT00850070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
Study NCT00020683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incyclinide
Description: High dose given orally
Study NCT00020683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incyclinide
Description: Low dose given orally
Study NCT01656304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01656304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00020683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02949648 — intervention group
Intervention type: DEVICE
Intervention: Electronic cigarette
Description: Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
Study NCT00322699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole bladder laser light treatment as an alternative to radical cystectomy
Description: The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
Study NCT01073345 — intervention group
Intervention type: PROCEDURE
Intervention: Portal venous flow
Description: Portal venous flow is measures using a noninvasive method (Doppler flow meter)
Study NCT00322699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photofrin
Description: The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
Study NCT01073345 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatic artery flow
Description: Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)
Study NCT02003651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quick Defense
Description: Echinacea product from Gaia Herbs.
Study NCT02003651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01477892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose remifentanil
Description: non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
Study NCT01477892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose remifentanil
Description: non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
Study NCT04279561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 68Ga-PSMA-11 PET/CT
Study NCT04279561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT04279561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 68Ga-PSMA-11 PET/CT
Study NCT03259334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Participants will receive 1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
Study NCT03259334 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 mL of sterile aqueous buffered solution.
Study NCT00767780 — intervention group
Intervention type: DEVICE
Intervention: APOS biomechanical gait system
Description: a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
Study NCT01724736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Study NCT01724736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Study NCT01724736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NM504:
Description: Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Study NCT01724736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NM504:
Description: Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Study NCT02352051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
Study NCT02983214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02983214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Study NCT02735187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue light treatment
Description: Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.
Study NCT02352051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
Study NCT02021058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Formula
Description: Experimental formula
Study NCT02021058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard control formula
Description: Standard Infant formula
Study NCT02735187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)
Study NCT01007708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-108
Description: Topical application once a day for 48 weeks
Study NCT01007708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application once a day for 48 weeks
Study NCT00603538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871 + carboplatin + paclitaxel
Description: Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
Study NCT00608933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
Study NCT00608933 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: educational intervention
Description: Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
Study NCT04032496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contemplative-Based Intervention for People Living with SLE
Description: Intervention sessions will follow a 6-week format consisting of weekly in-person sessions as well as guided homework to encourage practice at home. Some mindfulness practices that will be included are meditation, group exercise (yoga), group discussions, and deep breathing. Both participants diagnosed with SLE as well as caregivers will participate in the intervention sessions. 5 sessions will be approximately 2 hours long, while the final session will be approximately 4 hours long. Each intervention group will include approximately 4 participants with SLE and 4 caregivers.
Study NCT04032496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program (HEP)
Description: The HEP was designed to create an active control for mindfulness-based stress reduction (MBSR) interventions. The structure of this intervention will mirror that of the other arm of this study, but will lack the mindfulness component. The HEP includes topics such as physical activity, functional movement, music therapy, and nutrition education.
Study NCT03435991 — intervention group
Intervention type: OTHER
Intervention: Validation Experience Sampling Method 'Uromate'
Description: In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.
Study NCT03182205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IME
Description: The IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets. Inspiratory load will be set at 40% of maximum static inspiratory pressure. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a clip nasal.